Ajufo H et al. Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis. ASH 2023;Abstract 3207.

Bhave RR et al. Top advances of the year: Myeloproliferative neoplasms. Cancer 2023;129(23):3685-91. Abstract

Kong T et al. Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms. Am J Hematol 2023;98(7):1029-42. Abstract

Mascarenhas J, Mesa R. Cross-study comparison of JAK2 inhibitors in myelofibrosis: Risks and recommendations. Clin Lymphoma Myeloma Leuk 2023;23(10);714-8. Abstract

Mohan S et al. Phase 1/2 study of the activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis. ASH 2023;Abstract 624.

Moyo KT et al. PI3K inhibition restores and amplifies response to ruxolitinib in patients with myelofibrosis. Clin Cancer Res 2023;29(13):2375-84. Abstract

Oh ST et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 2023;7(19):5825-42. Abstract

Pemmaraju N et al. Transoform-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib plus placebo in patients with untreated myelofibrosis. ASH 2023;Abstract 620.

Rampal RK et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naive patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study. ASH 2023;Abstract 628.

Ritchie EK et al. Durability of hematocrit control in polycythemia vera with the first-in-class hepcidin mimetic rusfertide: Two-year follow up results from the REVIVE study. ASH 2023;Abstract 745.

Tantravahi SK et al. Selinexor plus ruxolitinib in JAK inhibitor (JAKi)-naïve patients with myelofibrosis: Long-term follow-up from XPORT-MF-034 suggestive of disease modification. ASH 2023;Abstract 622.

Tremblay D, Mesa R. New treatments for myelofibrosis. Curr Treat Options Oncol 2023;24(2):61-75. Abstract

Vachhani P et al. Platelet response in pacritinib-treated patients with cytopenic myelofibrosis: A retrospective analysis of PERSIST-2 and PAC203 studies. ASH 2023;Abstract 4554.

Verstovsek S et al. Ten years of treatment with ruxolitinib for myelofibrosis: A review of safety. J Hematol Oncol 2023;16(1):82. Abstract

Vidal GA et al. Advancing Inclusive Research (AIR) Site Alliance: Facilitating the inclusion of historically underrepresented people in oncology and ophthalmology clinical research. Contep Clin Trials 2024;137:107416. Abstract